GCP-2/CXCL6 蛋白, Human (HEK293, His)

CXCL6 (also known as granulocyte chemotactic protein-2, GCP-2), a member of the ELR+ CXC chemokine family, is a chemoattractant for neutrophilic granulocytes and initiates chemotaxis through the chemokine receptors CXCR1 and CXCR2^[1][2]. CXCL6 exerts neutrophil-activating and angiogenic activities, and has antibacterial action against Gram-negative and Gram-positive bacteria^[3]. GCP-2/CXCL6 Protein, Human (HEK293, His) is produced in HEK293 cells with six C-Terminal His-tags. It consists of 77 amino acids (G38-N114).

CXCL6（也称为 GCP-2）是一种 CXC 趋化因子，在炎症过程中由巨噬细胞以及上皮细胞和间质细胞表达。通过结合和激活其受体（CXCR1 和 CXCR2），它发挥中性粒细胞激活和血管生成活性。此外，CXCL6 还具有抗菌作用^[1][3]。
CXCL6 是一种 ELR 阳性 CXC 趋化因子，长度为 77 个氨基酸。NH2 末端谷氨酸-亮氨酸-精氨酸 (ELR) 基序是 CXC 趋化因子与 G 蛋白偶联受体 CXCR1 和 CXCR2 相互作用的特征。ELR+ CXC 家族包括 IL-8、生长调节癌基因（GRO-α、-β-γ）和 ENA-78。CXCL6 的结构与 ENA-78 的同源性 >75%，但其独特之处在于它与 CXCR1 和 CXCR2 均具有高亲和力结合。GCP-2 与 IL-8 类似，通过与 CXCR-1 和 CXCR-2 结合来激活靶细胞。两种受体均由中性粒细胞表达，但其他血液来源的细胞（例如淋巴细胞或单核细胞）不表达。CXCL6 激活内皮细胞会引起有丝分裂反应，从而导致血管生成。CXCL2 由气道、眼睛、胃肠道、乳腺、扁桃体、巨噬细胞和间充质细胞的上皮细胞表达，特别是在炎症期间。脂多糖（LPS）和促炎细胞因子TNF-α和IL-1β上调CXCL6的表达，而γ干扰素则具有下调作用^[1][2][3]。
CXCL6 通过与人类趋化因子受体 CXCR1 和 CXCR2 相互作用介导炎症、免疫反应、细胞生长和转移等多种过程。CXCL6 具有有效的趋化和促血管生成特性。CXCL6 在结直肠癌、乳腺癌、肺癌和甲状腺癌中过度表达。此外，CXCL6 在亚微摩尔浓度下对与粘膜感染相关的革兰氏阳性和革兰氏阴性病原菌具有抗菌活性^{[1][2] [3]}.

Recombinant CXCL6 (10 ng/mL) significantly inhibits both Sirt3 mRNA and protein levels, however, the AKT and FOXO3a phosphorylation significantly increased in human brain microvascular endothelial cells (HBMECs)^[2].
Recombinant human CXCL6 (0 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 10 ng/mL; 72 h) elicites enhanced proliferation of HUVECs in a dose-dependent manner, and co-culture with fibroblasts caused significantly enhanced HUVEC proliferation. Recombinant CXCL6 also promotes the proliferation of HUVECs in a concentration-dependent manner^[4].
Recombinant human CXCL6 (0 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 10 ng/mL; 24 h) significantly promotes cancer cell invasion in HT-29 cells^[4].

Human

HEK293

C-6*His

P80162 (G38-N114)

6372  [NCBI]

GPVSAVLTELRCTCLRVTLRVNPKTIGKLQVFPAGPQCSKVEVVASLKNGKQVCLDPEAPFLKKVIQKILDSGNKKN

Approximately 13 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, 5% Trehalose, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Pooja Mittal, et al. CXCL6 (granulocyte chemotactic protein-2): a novel chemokine involved in the innate immune response of the amniotic cavity. Am J Reprod Immunol. 2008 Sep;60(3):246-57.  [Content Brief]

  [2]. Xiaolin Wang, et al. CXCL6 regulates cell permeability, proliferation, and apoptosis after ischemia-reperfusion injury by modulating Sirt3 expression via AKT/FOXO3a activation. Cancer Biol Ther. 2021 Jan 2;22(1):30-39.  [Content Brief]

  [3]. Helena M Linge, et al. The human CXC chemokine granulocyte chemotactic protein 2 (GCP-2)/CXCL6 possesses membrane-disrupting properties and is antibacterial. Antimicrob Agents Chemother. 2008 Jul;52(7):2599-607.  [Content Brief]

  [4]. Jia-Chi Ma, et al. Fibroblast-derived CXCL12/SDF-1α promotes CXCL6 secretion and co-operatively enhances metastatic potential through the PI3K/Akt/mTOR pathway in colon cancer. World J Gastroenterol. 2017 Jul 28;23(28):5167-5178.  [Content Brief]